



California Institute for Regenerative Medicine

Independent Citizens Oversight Committee

FY 2023/24 Audit Results

January 29, 2026

California Institute for Regenerative Medicine Agenda

SECTION I

Scope of Services and Deliverables

SECTION II

Audit Results

SECTION III

Operational Highlights

SECTION IV

Required Communications

California Institute for Regenerative Medicine

Scope of Services and Deliverables

Scope of Services

- Audit of Basic Financial Statements (FY 2024)

Deliverables

- Independent Auditor's Report
- Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*
- Required Communications at the Conclusion of the Audit

California Institute for Regenerative Medicine

Audit Results

Financial Statements

- Unmodified Opinions
- No findings or deficiencies for internal control over financial reporting
- No findings or deficiencies for internal control over compliance

Clean (Unmodified) Audit Opinion

- The financial statements present fairly, in all material respects, CIRM's financial position and results of operations in accordance with GAAP.
- There were no material misstatements, no scope limitations, and no disagreements with management.
- Under Government Auditing Standards, tested control over financial reporting. No findings identified.
- Furthermore, no instances of noncompliance with laws or regulations.

California Institute for Regenerative Medicine

Operational Highlights

Increase in Financial Position and Liquidity

- Net position increased by \$124.0 million, from \$213.8 million to \$337.3 million
- Cash and investments increased by \$121.3 million, ending the year at \$337.3 million
 - Mainly driven by Proposition 14 GO bond proceeds of \$383.9 million and Proposition 71 commercial paper of \$52.8 million
 - Higher investment earnings

California Institute for Regenerative Medicine

Operational Highlights (continued)

Major Program Spending

Research grants totaled \$299.2 million, representing majority of total expenses.
- Increase of \$104.0 million year over year

Stem Cell Research and Cures Fund (6047)

- Grant expenditures increased significantly, as fund works towards fully expending Proposition 71 authorized funding.

CA Stem Cell Research and Cures Fund of 2020 (6091)

- Increased payments as overall activity increases with new grants awarded in the current year and milestones meeting completion of grants from prior years

Licensing Revenues and Royalties Fund (1031)

- No activities during the current year, CIRM is working towards developing a formal plan to begin enrolling eligible patients for assistance awards.

California Institute for Regenerative Medicine

Required Communications

Report to the Independent Citizens Oversight Committee

Significant accounting policies and practices	Significant policies in Note 1 to basic financial statements. No new standards implemented having significant impacts on the CIRM's reporting
Significant accounting estimates	Office lease accounted for under GASB No. 87, <i>Leases</i> CIRM appropriately uses the methodology and calculation template provided by the SCO.
Financial presentation and disclosure omissions	Note 1 appropriately discloses CIRM's Pension and OPEB arrangements, and the lack of allocated liabilities from the SCO.
Corrected and uncorrected audit misstatements	No material corrected misstatements. No uncorrected misstatements, other than those that are clearly trivial.
Difficulties encountered in performing the audit	No matters reported.
Other information included in the annual report	Dolby Grants Schedule of Revenues, Expenditures and Changes in Available Resources, no material inconsistencies identified from the audited financial statements.
Disagreements with management	No matters reported.
Management consultations with other independent accountants	No matters reported.
Subsequent event	No matters reported.

Questions?

This presentation to the Independent Citizens Oversight Committee (ICOC) is intended solely for the information and use of the ICOC and is not intended to be and should not be used by anyone other than these specified parties. This presentation is not intended for general use, circulation or publication and should not be published, circulated, reproduced or used for any purpose without our prior written permission in each specific instance.

